BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

We are proud to be recognized on the Deloitte 2020 Technology Fast 500 list
BDSI Products

Marketed Products

BDSI makes innovative therapies available.

BDSI offers a diverse portfolio of solutions for the treatment of chronic pain and other serious and debilitating chronic conditions.



BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA®) technology.

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to buprenorphine

For more information on BELBUCA® visit

Medication Guide Full Prescribing Information


Symproic® (naldemedine) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.

  • Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction
  • Patients with a history of a hypersensitivity reaction to naldemedine

For more information on Symproic® visit

Medication Guide Full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, 1-800-FDA-1088. Report an Adverse Event

BELBUCA®, BDSI®, and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. All other trademarks and trade names are the property of their respective owners.

Recent BDSI News

May 6, 2021

Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery

Read more
April 20, 2021

RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021

Read more
March 10, 2021

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
June 11, 2021BDSI $3.65/ - -0.54%
Data provided by Nasdaq. Minimum 15 minutes delayed.